Gene therapy Competitive Landscape Report 2023 (Updated) | Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, and others.

Posted on
by

Gene therapy Competitive Landscape Report 2023 (Updated) | Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, and others.

DelveInsight’s, “Gene Therapy Competitive Landscape 2023” report provides comprehensive insights about 250+ Gene Therapy companies and 300+ Gene Therapy drugs in the Gene therapy Competitive landscape. It covers the Gene Therapy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Gene Therapy Competitive Landscape Report

  • DelveInsight’s Gene Therapy report depicts a robust space with 250+ active players working to develop 300+ pipeline therapies for Gene Therapy treatment.
  • The leading companies working in the Gene Therapy Market include Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, Istari Oncology, Immvira Pharma, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Mustang Bio, Virogin Biotech, Memgen, Replimune, Immvira Pharma, PsiOxus Therapeutics, VCN Biosciences, Sorrento Therapeutics, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, DNAtrix, and others.
  • Promising Gene Therapy Therapies in the various stages of development include ABECMA, ADSTILADRIN, ALLOCOR, BREYANZI, CARVYKTI, CLEVECORD, Ducord, HPC Cord Blood, GINTUIT and others.
  • December 2023: Sangamo Therapeutics announced a study of Phase 1 & 2 clinical trials for ST-920. This is the first in human treatment with ST-920, a recombinant AAV2/6 vector encoding the cDNA for human a-Gal A. The purpose of this study is to evaluate the safety and tolerability of ascending doses of ST-920. ST-920 aims to provide stable, long-term production of α-Gal A at therapeutic levels in subjects with Fabry disease. The constant production of α-Gal A in humans should, importantly, enable reduction and potentially clearance of Fabry disease substrates Gb3 and lyso-Gb3.
  • December 2023: Regenxbio Inc. announced a study of Phase 1 & 2 clinical trials for RGX-202. RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne.

 

Request a sample and discover the recent advances in Gene Therapy @ Gene Therapy Competitive Landscape Report

 

The Gene Therapy report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Gene Therapy report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

 

Gene Therapy Overview

Gene therapy is a technique that uses a gene(s) to treat, prevent or cure a disease or medical disorder. Often, gene therapy works by adding new copies of a gene that is broken, or by replacing a defective or missing gene in a patient’s cells with a healthy version of that gene. Both inherited genetic diseases (e.g., hemophiliaand sickle cell disease) and acquired disorders (e.g., leukemia) have been treated with gene therapy.

 

Find out more about Gene Therapy Analytical Perspective: In-depth Commercial Assessment @ Gene Therapy Collaboration Analysis by Companies

 

Gene Therapy Companies and Therapies

  • Candel Therapeutics: CAN-2409
  • CRISPR Therapeutics: CTX001
  • TILT Biotherapeutics: TILT-123
  • Akamis Bio: NG-347

 

Gene Therapy Competitive Landscape

The Gene Therapy report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

Gene Therapy Pipeline Report Assessment

  • Gene Therapy Company Analysis
  • Gene Therapy Therapeutic Assessment
  • Gene Therapy Pipeline Assessment
  • Gene Therapy Inactive drugs assessment
  • Gene Therapy Unmet Needs

 

Learn more about the emerging Gene Therapy Competitive Landscape @ Gene Therapy Market Drivers and Barriers, Unmet Needs

 

Scope of the Gene Therapy Report

  • Coverage- Global
  • Gene Therapy Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
  • Gene Therapy Companies- Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, Istari Oncology, Immvira Pharma, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Mustang Bio, Virogin Biotech, Memgen, Replimune, Immvira Pharma, PsiOxus Therapeutics, VCN Biosciences, Sorrento Therapeutics, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, DNAtrix, and others.
  • Gene Therapy Therapies- ABECMA, ADSTILADRIN, ALLOCOR, BREYANZI, CARVYKTI, CLEVECORD, Ducord, HPC Cord Blood, GINTUIT and others.

 

Dive deep into rich insights for new drugs for Gene Therapy Product Developmental Activities, Visit @ Gene Therapy Research and Development Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Gene Therapy: Overview
  4. Gene Therapy -Analytical Perspective: In-depth Commercial Assessment
  5. Competitive Landscape
  6. Therapeutic Assessment
  7. Gene Therapy: Company and Product Profiles (Marketed Therapies)
  8. Juno Therapeutics, Inc./Bristol-Myers Squibb
  9. BREYANZI
  10. Gene Therapy: Company and Product Profiles (Pipeline Therapies)
  11. Late Stage Products (Phase III)
  12. Candel Therapeutics
  13. CAN-2409
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II)
  16. Company Name
  17. Product Name
  18. Drug profiles in the detailed report…..
  19. Early Stage Products (Phase I)
  20. TILT Biotherapeutics
  21. TILT-123
  22. Drug profiles in the detailed report…..
  23. Preclinical and Discovery Stage Products
  24. Company Name
  25. Product Name
  26. Drug profiles in the detailed report…..
  27. Inactive Products
  28. Gene Therapy- Unmet needs
  29. Gene Therapy – Market drivers and barriers
  30. Appendix

 

For further information on the Gene Therapy Report @ Gene Therapy Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market